We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

MERIDIAN BIOSCIENCE

Meridian Bioscience manufactures, markets, and distributes diagnostic test kits, purified reagents and biopharmaceuti... read more Featured Products: More products

Download Mobile App




Meridian Bioscience Launches Two New Master Mixes That Detect DNA and RNA in Crude Saliva Samples

By LabMedica International staff writers
Posted on 01 Feb 2022

Meridian Bioscience, Inc. More...

(Cincinnati, OH, USA) has launched two new master mixes that detect DNA and RNA in crude saliva samples.

These two new mixes, Lyo-Ready Direct DNA qPCR Saliva Mix and Lyo-Ready Direct RNA/DNA qPCR Saliva Mix can be used in liquid format or lyophilized. Both mixes accelerate the development of diagnostic assays and improve assay sensitivity using saliva samples with direct qPCR protocols. Saliva is a non-invasive clinical sample utilized for diagnostic testing across many diseases, including cancer, HIV, and respiratory diseases (e.g., flu, bronchiolitis, pneumonia, and COVID-19). Saliva is one of the easiest samples to collect and handle; however, PCR inhibitors naturally present in high concentrations in the sample create challenges in developing highly sensitive and reliable saliva-based assays.

Similar to the innovative portfolio of Air-Dryable sample-specific master mixes, Meridian's new Lyo-Ready saliva-specific master mixes are optimized for use on crudely processed saliva or sputum samples for enhanced assay sensitivity and flexible protocols. They are "ready-to-use," with no further optimization required aside from the addition of primers and probes. Additionally, these mixes are stable in a liquid format or can be lyophilized to create ambient temperature-stable assays for point-of-care applications.

"With the surge of COVID-19 infections caused by the Omicron variant along with a rapid increase of other respiratory infections, the need for direct saliva testing has never been greater," said Lourdes Weltzien, Ph.D., Executive Vice President - Life Science. "Direct RT-qPCR saliva assays offer fast and convenient sample analysis, improve logistics and reduce costs involved in sample handling and transport. We are pleased to be the first to offer a complete solution for anyone developing a saliva-based molecular assay, whether in liquid, lyophilized or air-dried format."

Related Links:
Meridian Bioscience, Inc.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Connectivity Solution
EKF Link
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Two major international studies identified noninvasive tests that can accurately diagnose and assess MASLD and MASH, reducing reliance on liver biopsy. (Image Credit: Adobe Stock)

Noninvasive Tests Offer Alternatives to Biopsy for Assessing Advanced Liver Scarring

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects up to one in three adults worldwide and as many as seven in 10 people with obesity or type 2 diabetes. Its more severe form, metabolic... Read more

Hematology

view channel
Image: Mayo Clinic researchers used genetic data from nearly 50,000 participants to identify sickle cell and beta-thalassemia carrier traits, highlighting how population-scale testing can complement existing screening (Image Credit: Adobe Stock)

Genetic Testing Offers Opportunities for Earlier Blood Disorder Carrier Identification

Inherited hemoglobin disorders can affect oxygen transport, yet individuals who carry only a trait may remain unaware of their status. People with sickle cell trait or beta-thalassemia trait often have... Read more

Microbiology

view channel
Image: Graphical Abstract (Andrew Medina-Marino, Chibuzor M Babalola, Mandisa M Mdingi, et al. Clinical Infectious Diseases, 2026. doi:10.1093/cid/ciag577.)

Repeat Prenatal STI Screening and Treatment May Reduce Preterm Births

Preterm birth remains a major obstetric concern and is associated with serious complications in early childhood. Common sexually transmitted infections during pregnancy often cause no symptoms, making... Read more

Pathology

view channel
Image Credit: Adobe Stock

AI Pathology Approach Closely Aligns With Breast Cancer Genomic Risk Classification

In early-stage breast cancer, precision oncology relies on biological information to guide personalized treatment decisions. Because access to tissue-based genomic testing may be limited, there is growing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.